secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-09-14T11:29:42+00:00
Accession:  0001193125-26-389844
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zipalertinib+chemo meets primary endpoint in Phase 3 REZILIENT3: PFS 14.5 vs 8.5 mo, HR 0.50
--------------------------------------------------------------------------------

- Median PFS 14.5 vs 8.5 months (HR 0.50; 95% CI 0.34-0.73; P=0.00015) in first-line EGFR ex20ins NSCLC.
- ORR 65.0% vs 40.3% (P<0.0001); median duration of response 14.2 vs 9.9 months.
- Interim OS HR 0.72 (95% CI 0.42-1.23) at 30% maturity; follow-up ongoing.
- Safety: Grade ≥3 AEs 87.1% vs 54.4%, mostly manageable hematologic; no new signals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526389844/0001193125-26-389844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526389844/cgem-20260913.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-389844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer